Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 9/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880460 | 0.87 | KIT (0.41) | TNKSTNKS2KITPARP1THRB | |
| SCHEMBL5880632 | 0.86 | ACHE (0.43) | KITPDE10A | |
| SCHEMBL5880586 | 0.85 | ACHE (0.52) | KITPDE10A | |
| SCHEMBL5880524 | 0.85 | ALDH1A1 (0.43) | KITPDE10A | |
| SCHEMBL5880447 | 0.83 | PDE10A (0.52) | PDE10A | |
| SCHEMBL5880463 | 0.81 | KDM4E (0.42) | KITPDE10ATHRBPDE3A | |
| SCHEMBL5880491 | 0.79 | KIT (0.39) | TNKSTNKS2KITPARP1THRB | |
| SCHEMBL5880492 | 0.79 | KIT (0.39) | TNKSTNKS2KITPARP1THRB | |
| SCHEMBL5880461 | 0.77 | EGFR (0.51) | KITTHRB | |
| SCHEMBL5880643 | 0.74 | CYP1A1 (0.38) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091200-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX U.S.A. LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-6900220-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | BECKER CYRUS K (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1363899-B1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | TNKS 3349/4885TNKS2 3458/4885NTSR1 231/4885 |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | TNKS 3584/4885TNKS2 3702/4885NTSR1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.